Home › Pancreatic Cancer › NCT01102569
Pancreatic Cancer Genetics
Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients diagnosed with pancreatic cancer. * Patients are of Ashkenazi Jewish descent. * Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154). Exclusion Criteria: * Inability to provide informed consent. * Under the age of 18 years old.
About the study
The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
Sponsor: Columbia University · Participants: 100 · Started: 2008-01
Contact the study team
- Fay Kastrinos, MD · Phone: 212-305-1021
- Vilma Rosario · Phone: 212-305-6033
Official record on ClinicalTrials.gov — NCT01102569
Locations in the U.S.
| New York | Columbia University Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.